NCT00755846 - Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Type 2 Diabetes. | Biotech Hunter

Enrollment

265

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2005

Conditions

Diabetes Mellitus

Interventions

DRUG

Alogliptin

Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks

DRUG

Alogliptin

Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.

DRUG

Alogliptin

Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.

DRUG

Alogliptin

Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks.

DRUG

Alogliptin

Alogliptin 100 mg, tablets, orally, once daily for up to 12 weeks.

DRUG

Placebo

Alogliptin placebo-matching tablets, orally, once daily for up to 12 weeks.